Erratum: CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models (Cancer Research (September 15, 2003) (5978-5991))
Bruce Ruggeri, Craig A. Dionne, Diane E. Gingrich, J. B. Singh(Panjab University), Jeffrey Vaught, Susan Jones‐Bolin, Kathryn Hunter, John T. Isaacs(Brady (Norway)), John P. Mallamo, Paweł Dobrzański, Shi Yang(Boston Medical Center), Bernard Bourie(Johns Hopkins University), Robert L. Hudkins(State Street (United States)), Mark A. Ator, Mark S. Albom, Andres J. Klein–Szanto, Lisa D. Aimone, Paul Schaeffer(Universidad La Salle), Pierre Casellas(Université de Montpellier), Françoise Bono(OSE Immunotherapeutics (France)), Candy Robinson, Hong Chang, Jean Marc Herbert(Sanofi (France)), Роберто Пили(Jacobs Institute), Thelma S. Angeles, Sonya Pritchard
Cancer Research
November 1, 2003
Cited by 0
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
PGC-1α Deficiency Causes Multi-System Energy Metabolic Derangements: Muscle Dysfunction, Abnormal Weight Control and Hepatic Steatosis
|PLoS Biology|2005|943
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
|Proceedings of the National Academy of Sciences|2008|723